Commerce Bank Takes Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Commerce Bank acquired a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 6,789 shares of the biopharmaceutical company's stock, valued at approximately $204,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of TGTX. Altium Capital Management LLC bought a new stake in shares of TG Therapeutics during the fourth quarter worth about $2,860,000. NewEdge Advisors LLC grew its holdings in TG Therapeutics by 4,549.7% during the 4th quarter. NewEdge Advisors LLC now owns 6,928 shares of the biopharmaceutical company's stock worth $209,000 after acquiring an additional 6,779 shares during the last quarter. XTX Topco Ltd bought a new stake in TG Therapeutics during the 4th quarter worth approximately $400,000. Summit Investment Advisors Inc. increased its position in TG Therapeutics by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company's stock valued at $440,000 after acquiring an additional 463 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in shares of TG Therapeutics during the fourth quarter worth $14,508,000. Institutional investors own 58.58% of the company's stock.

TG Therapeutics Trading Up 3.8 %

Shares of TG Therapeutics stock traded up $1.65 on Wednesday, reaching $45.51. 3,267,648 shares of the company's stock were exchanged, compared to its average volume of 3,072,435. The company has a market capitalization of $7.23 billion, a P/E ratio of -455.05 and a beta of 2.14. TG Therapeutics, Inc. has a 52 week low of $14.87 and a 52 week high of $45.83. The firm's 50-day moving average is $37.95 and its two-hundred day moving average is $32.90. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The company had revenue of $108.19 million for the quarter, compared to analysts' expectations of $100.67 million. Sell-side analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

TGTX has been the subject of several analyst reports. StockNews.com raised TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. HC Wainwright restated a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, TG Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $40.67.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.